1. Medtech Insight
  2. >>Policy & Regulation

Want to Have It All? Work In Government, Attorney Says

An interview with FDA lawyer Anne Walsh

 
• By Hannah Daniel

Anne Walsh speaks to Medtech Insight about her practical advice for women in the legal field and why she volunteers to provide networking opportunities for female lawyers.

Anne Walsh
• Source: Hyman, Phelps & McNamara, P.C.

Friday, March 8 is International Women’s Day. To celebrate the day and Women’s History Month, Medtech Insight spoke with female leaders in medtech, regulatory and health care delivery about their experiences as women, women-specific industry challenges including research and innovation needs, and how women in leadership roles today are inspiring and empowering rising generations.

If you want to work in government law, you should first work

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

Access To Library Tools Being Restored At US FDA

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.

FDA Announces Classifications On 9 Device Types

 
• By Elizabeth Orr

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.